1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 51-60 of 72 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the diamond studyDent, J.; Vakil, N.; Jones, R.; Bytzer, P.; Schnoning, U.; Halling, K.; Junghard, O.; Lind, T.
2008A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux diseaseDent, J.; Kahrilas, P.; Hatlebakk, J.; Vakil, N.; Denison, H.; Franzen, S.; Lundborg, P.
2010Primary radiotherapy in progressive optic nerve sheath meningiomas: a long-term follow-up studySaeed, P.; Blank, L.; Selva-Nayagam, D.; Wolbers, J.; Nowak, P.; Geskus, R.; Weis, E.; Mourits, M.; Rootman, J.
2013Smoking termination opportunity for in patients (STOP): Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 12-month randomised controlled trial for inpatientsSmith, B.; Carson, K.; Brinn, M.; Labiszewski, N.; Peters, M.; Fitridge, R.; Koblar, S.; Jannes, J.; Veale, A.; Goldsworthy, S.; Litt, J.; Edwards, D.; Esterman, A.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2009Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMuller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
2010Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.
2002Graft loss following renal transplantation in Australia: is there a centre effect?Briganti, E.; Wolfe, R.; Russ, G.; Eris, J.; Walker, R.; McNeil, J.
2004Escitalopram: superior to citalopram or a chiral chimera?Svensson, S.; Mansfield, P.
2015Recent trends in early stage response to combination antiretroviral therapy in AustraliaMcManus, H.; Hoy, J.; Woolley, I.; Boyd, M.; Kelly, M.; Mulhall, B.; Roth, N.; Petoumenos, K.; Law, M.

Discover